title: Comparison of a recombinant endotoxin-neutralizing protein with a human monoclonal antibody to endotoxin for the treatment of Escherichia coli sepsis in rats.
abstract: A recombinant endotoxin-neutralizing protein (ENP) from Limulus polyphemus and a monoclonal IgM anti-lipid A antibody (HA-1A) were compared in a rat model of Escherichia coli sepsis. One hour after intraperitoneal challenge with 10(6) cfu of E. coli O18ac K1, animals were sensitized to endotoxin with lead acetate and treated with ENP, HA-1A, or saline, followed by ceftriaxone and gentamicin. Before treatment, 95% of rats had high-grade bacteremia and high serum endotoxin concentrations, which were similar in all treatment groups (P > .60). One hour after treatment, there was no bacterial growth in any blood sample, and endotoxin concentrations were significantly lower in the ENP group than in the HA-1A and saline groups (P < .01). At 24 h after challenge, survival in the ENP group was significantly higher than in the HA-1A saline group (P < .001). ENP improved survival in a rat model of E. coli sepsis with high mortality despite effective antibiotic therapy.
authors.affiliation: Department of Medicine, Children's Hospital, Boston, Massachusetts.
authors.forename: N
authors.initials: N
authors.lastname: Kuppermann
authors.forename: D S
authors.initials: DS
authors.lastname: Nelson
authors.forename: R A
authors.initials: RA
authors.lastname: Saladino
authors.forename: C M
authors.initials: CM
authors.lastname: Thompson
authors.forename: F
authors.initials: F
authors.lastname: Sattler
authors.forename: T J
authors.initials: TJ
authors.lastname: Novitsky
authors.forename: G R
authors.initials: GR
authors.lastname: Fleisher
authors.forename: G R
authors.initials: GR
authors.lastname: Siber
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D023181:Antimicrobial Cationic Peptides; D060829:Arthropod Proteins; D016470:Bacteremia / Q000628:therapy*; D004731:Endotoxins / Q000276:immunology; D004927:Escherichia coli Infections / Q000628:therapy*; D005688:Galactosamine / Q000633:toxicity; D006737:Horseshoe Crabs; D007075:Immunoglobulin M / Q000627:therapeutic use*; D007447:Invertebrate Hormones / Q000627:therapeutic use*; D008050:Lipid A / Q000276:immunology*; D008297:Male; D009942:Organometallic Compounds / Q000633:toxicity; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D023181:Antimicrobial Cationic Peptides; D060829:Arthropod Proteins; D004731:Endotoxins; D007075:Immunoglobulin M; D007447:Invertebrate Hormones; D008050:Lipid A; D009942:Organometallic Compounds; D011994:Recombinant Proteins; C034705:antilipopolysaccharide factor (Limulus); D005688:Galactosamine; C008261:lead acetate